Aquestive Therapeutics (AQST) Income from Continuing Operations (2017 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Income from Continuing Operations of 8057000.0 for Q1 2026, up 64.86% year-over-year from 4887099.17 in Q1 2025, and up 74.71% quarter-over-quarter from 31860000.0 in Q4 2025.
Aquestive Therapeutics (AQST) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 8057000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 64.86% year-over-year to 8057000.0; the TTM figure through Mar 2026 stood at 68911000.0 (down 27.05% YoY), while the FY2025 annual figure was 83784000.0, down 89.83% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 8057000.0, up from 31860000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 8068000.0 in Q1 2023, with the low at 31860000.0 in Q4 2025.
- The 5-year median for Income from Continuing Operations is 12536000.0 (2022), against an average of 11662235.29.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations jumped 161.03% in 2023, then tumbled 465.55% in 2024.
- Aquestive Therapeutics' Income from Continuing Operations stood at 12352000.0 in 2022, then soared by 34.33% to 8111000.0 in 2023, then tumbled by 110.27% to 17055000.0 in 2024, then slumped by 86.81% to 31860000.0 in 2025, then jumped by 74.71% to 8057000.0 in 2026.
- Business Quant data shows AQST's Income from Continuing Operations at 8057000.0 in Q1 2026, 31860000.0 in Q4 2025, and 15446000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Aquestive Therapeutics | 583.72 Mn | 583.72 Mn | 9.80 Mn | -22.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.86 Mn |
| Mar 31, 2026 | -8.06 Mn |
| Dec 31, 2025 | -31.86 Mn |
| Sep 30, 2025 | -15.45 Mn |
| Jun 30, 2025 | -13.55 Mn |
| Mar 31, 2025 | -22.93 Mn |
| Dec 31, 2024 | -17.06 Mn |
| Sep 30, 2024 | -11.51 Mn |
| Jun 30, 2024 | -2.75 Mn |
| Mar 31, 2024 | -12.83 Mn |
| Dec 31, 2023 | -8.11 Mn |
| Sep 30, 2023 | -2.04 Mn |
| Jun 30, 2023 | -5.79 Mn |
| Mar 31, 2023 | 8.07 Mn |
| Dec 31, 2022 | -12.35 Mn |
| Sep 30, 2022 | -12.54 Mn |
| Jun 30, 2022 | -16.30 Mn |
| Mar 31, 2022 | -13.22 Mn |
| Dec 31, 2021 | -28.95 Mn |
| Sep 30, 2021 | -14.56 Mn |